Idiopathic pulmonary fibrosis (IPF) is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The cause of IPF is unknown, and currently there is no FDA approved treatment. IPF occurs primarily in people 40 to 70 years of age. Based on the published scientific literature, median survival time from diagnosis is two to five years in patients with IPF, and most patients die from the complications associated with the disease. We believe that there are approximately 100,000 patients with IPF in the United States, and a similar number in Europe, approximately two-thirds of whom have mild to moderate disease severity.

InterMune has completed the Phase 3 CAPACITY program evaluating pirfenidone for the treatment of patients with IPF and a New Drug Application (NDA) has been accepted for Priority Review by the FDA.  

View our IPF animation (Windows Media format) Video use courtesy of Coalition for Pulmonary Fibrosis.

Investigational, not approved by the FDA.